Annexon Reports Promising Phase 2 Data For ANX007 In Geographic Atrophy Due To Dry AMD
22/10 05:44
(RTTNews) - Annexon Inc. (ANNX) announced new findings from its Phase 2 ARCHER study for ANX007 in geographic atrophy (GA) due to dry age-related macular degeneration (AMD). ANX007 demonstrated enhanced protection of vision and greater preservation of central photoreceptor cells...